Skip to content

Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04633798
Enrollment
100
Registered
2020-11-18
Start date
2020-12-01
Completion date
2020-12-21
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian Gland Dysfunction

Brief summary

To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland massage in treating meibomian gland dysfunction of different degrees ,focusing on effective rate, lasting time and changes of meibomian gland function and morphology.

Detailed description

To divide all participants into two groups, group one treated with IPL combined with Lipiflow and group two treated with IPL combined with meibomian gland massage.The following parameters were recorded after treatment: the effective rate, lasting time and changes of meibomian gland function and morphology.All parameters were compared between the two groups.

Interventions

PROCEDUREIPL/Lipiflow

To treat patients with MGD using intense pulsed light combined with lipiflow

PROCEDUREIPL/MGX

To treat patients with MGD using intense pulsed light combined with meibomian gland massage

Sponsors

Aier School of Ophthalmology, Central South University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with meibomian gland dysfunction * patients with ocular discomfort * skin type:FitzpatricⅠ-Ⅳ

Exclusion criteria

* patients with acute ocular inflammation * eye surgery history in the last 12 months * patients who have received IPL or Lipiflow in the last 12 months * patients who wear contact lens in last one month

Design outcomes

Primary

MeasureTime frameDescription
ocular surface disease index(OSDI)6 monthsThe OSDI is assessed on a scale of 0 to 100,with higher scores representing greater disability
meibomian gland expressibility score and meibum quality score6 monthsThe score is on a scale of 0 to 6.The higher scores, the severity of the meibomian gland function(the highest score is 6 and the lowest score is 0)
meibomian gland dropout score6 monthsthe higher scores, the severity of the meibomian gland morphology(The highest score is 6 and the lowest score is 0)
Breakup time6 monthsthe shorter time, the poorer of the tear film stability

Contacts

Primary ContactYan Chen, doctor
chinacy@hotmail.com+86-021-62956699

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026